Options for integration of mLSTs into multimodal concepts for prevention and treatment of leukemia relapse after hematopoietic stem cell transplantation (HSCT): production before HSCT or during engraftment, allowing for early adjuvant mLST infusion (A), drug-based bridging after engraftment until delayed adjuvant mLST infusion (B), and combining drug-based disease control of overt hematological relapse, followed by maintenance with mLST infusion and additional treatment based on the mechanism of relapse (C). Professional illustration by Somersault18:24.